- Home
- AXP vs AMGN Comparison
AXP vs AMGN Comparison
Compare AXP & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXP | AMGN |
|---|---|---|
| Founded | 1850 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.5B | 183.1B |
| IPO Year | 2005 | 2002 |
Fundamental Metrics
Financial Performance| Metric | AXP | AMGN |
|---|---|---|
| Price | $317.07 | $336.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 19 |
| Target Price | ★ $357.33 | $351.05 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | 1.20% | ★ 2.98% |
| EPS Growth | 9.78 | ★ 88.23 |
| EPS | ★ 4.28 | 3.34 |
| Revenue | ★ $27,819,000,000.00 | $25,424,000,000.00 |
| Revenue This Year | $19.81 | $5.00 |
| Revenue Next Year | $8.80 | $2.45 |
| P/E Ratio | ★ $73.43 | $100.97 |
| Revenue Growth | ★ 13.44 | 8.83 |
| 52 Week Low | $286.15 | $269.77 |
| 52 Week High | $387.49 | $391.29 |
Technical Indicators
Market Signals| Indicator | AXP | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 48.50 |
| Support Level | $314.46 | $334.95 |
| Resistance Level | $325.00 | $338.64 |
| Average True Range (ATR) | 5.29 | 6.89 |
| MACD | 0.35 | 1.32 |
| Stochastic Oscillator | 86.61 | 64.66 |
Price Performance
Historical ComparisonAbout AXP American Express Company
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. It operates in four segments: US consumer services, US commercial services, international card services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.